Trevi Therapeutics to Participate in Upcoming August Conferences

Core Viewpoint - Trevi Therapeutics, Inc. is advancing its investigational therapy Haduvio™ for chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), with upcoming participation in key biotech conferences [1][2]. Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment [2][5]. - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for patients with IPF chronic cough and RCC [2][5]. Industry Context - Chronic cough affects up to 85% of patients with IPF, with approximately 150,000 patients in the U.S. suffering from this condition [3]. - Patients with chronic cough may cough up to 1,500 times per day, leading to severe health impacts, including disease progression and reduced quality of life [3]. - There are currently no approved therapies for chronic cough in IPF patients, and existing off-label treatments offer minimal benefits [3]. - Refractory chronic cough, affecting around 2-3 million patients in the U.S., is characterized by a persistent cough lasting over 8 weeks without approved therapies [4].